

Cancer Association of South Africa (CANSA)




Fact Sheet on Somatostatinoma

Introduction

Somatostatinomas are rare tumours that can develop in the pancreas or small bowel. Pancreatic tumours most commonly develop in the head of the pancreas.

[Picture Credit: Pancreas]

Somatostatinomas develop in hormone producing cells in the pancreas called islet cells. There are different types of islet cells, each producing different hormones. Delta islet cells make the hormone somatostatin. Somatostatin cuts off production of other hormones by the pancreas and controls how the gut works. Somatostatinomas produce extra somatostatin, which eventually leads to symptoms.



Elangovan, A. & Zulfiqar, H. 2020.

“Somatostatinoma is a rare neuroendocrine tumor (NET) with an incidence of 1 in 40 million individuals and accounts for less than 5% of pancreatic NETs (pNETs). The tumor was first described in 1977 in a 46-year-old woman in the head of the pancreas. The tumor originates from the delta cells of the pancreas and predominantly contains somatostatin with trace quantities of other pancreatic hormones such as insulin, glucagon, gastrin, and vasoactive intestinal polypeptide. It remains localized to the pancreas in 56 to 70% of the cases, out of which 36% occur in the head, 14% in the pancreatic body, and 32% in the tail. Other common sites include duodenum (19%), ampulla of Vater (3%), and small bowel (3%). Reports exist of rare instances of extra-gastrointestinal primaries in the lungs, kidneys, and thyroid.”

Incidence of Somatostatinomas

The National Cancer Registry of 2016 does not furnish any information regarding Somatostatinoma.

Signs and Symptoms of Somatostatinoma

The following are typical signs and symptoms for Somatostatinoma:

- Excess somatostatin
- Mild hyperglycaemia
- Presence of gallstones
- Malabsorption problems
- Presence of excessive fat in faeces
- Weight loss
- Diagnosis of diabetes
- Cholestatic jaundice
- Presence of intestinal tumour
- Presence of a pancreatic tumour
- Reduced hydrochloric acid in digestive system
- Reduced gastric release

Martin, S., Fica, S., Parfeni, O., Popa, L., Manuc, T., Rizea, O., Lupescu, I., Gherghe, M., Becheanu, G. & Croitoru, A. 2020.

“Somatostatinomas are rare neuroendocrine tumors (NET) that arise in the gastrointestinal (GI) tract. Because of their insidious growth, they are usually asymptomatic until late stages, presenting as malignant disease. We report the case of a 50-year-old woman who presented with epigastric abdominal pain, diarrhea and significant weight loss in the last two years. On clinical examination the patient met the criteria for neurofibromatosis type 1 (NF1). Abdominal CT and MRI revealed an infiltrative duodenal mass, with pancreatic invasion, locoregional enlarged lymph nodes and disseminated hepatic nodules. Microscopy and immunohistochemistry uncovered a neuroendocrine tumor, staining positive for chromogranin A (CgA), synaptophysin and somatostatin, with a Ki67 = 1%. Somatostatin receptors (SSTRs) type 2 were negative and SSTRs type 5 were positive in less than 50% of tumoral cells. Our patient was classified as a T3N1M1 stage IV metastatic duodenal grade 1 somatostatinoma and treatment with somatostatin analogues and chemotherapy with capecitabine and temozolomide was started, with so far abdominal imaging follow-up showing stable disease. When a patient is diagnosed with a rare NET, such as a somatostatinoma, it is of utmost importance to determine if it is a sporadic tumor or just a feature of a genetic disorder.”

Treatment of Somatostatinoma

Since somatostatinomas have a high malignant potential, aggressive intervention is warranted. Surgical excision usually offers the only opportunity for long-term cure.

About Clinical Trials

Clinical trials are research studies that involve people. They are conducted under controlled conditions. Only about 10% of all drugs started in human clinical trials become an approved drug.

Clinical trials include:

- Trials to test effectiveness of new treatments
- Trials to test new ways of using current treatments
- Tests new interventions that may lower the risk of developing certain types of cancers
- Tests to find new ways of screening for cancer

The [South African National Clinical Trials Register](#) provides the public with updated information on clinical trials on human participants being conducted in South Africa. The Register provides information on the purpose of the clinical trial; who can participate, where the trial is located, and contact details.

For additional information, please visit: www.sanctr.gov.za/

Medical Disclaimer

This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this Fact Sheet. So far as permissible by law, the Cancer Association of South Africa (CANSA) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this Fact Sheet.

Whilst the Cancer Association of South Africa (CANSA) has taken every precaution in compiling this Fact Sheet, neither it, nor any contributor(s) to this Fact Sheet can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this Fact Sheet.



Sources and References Consulted or Utilised

American Association of Endocrine Surgeons

http://endocrinediseases.org/neuroendocrine/somatostatinoma_treatment.shtml

Cancer Research UK

<http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/somatostatinomas?script=true#what>

Elangovan, A. & Zulfiqar, H. 2020. Somatostatinoma. *In*: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. 2020 Sep 8.

Kilambi, R., Singh, A.N., Das, P., Madhusudhan, K.S. & Pal, S. 2018. Somatostatinoma masquerading as chronic pancreatitis. *Pancreas*. 2018 Apr;47(4):e19-e20. doi: 10.1097/MPA.0000000000001011.

Letelier, J., Bonotto, M.L. & Ardengh, J.C. 2016. Somatostatinoma of the minor duodenal papilla associated with pancreas divisum treated by endoscopic papillectomy. *Endoscopy*, 2016; (38 Suppl1):E135-137. doi: 10.1055/s-0042-104928. Epub 2016 Apr 14.

Martin, S., Fica, S., Parfeni, O., Popa, L., Manuc, T., Rizea, O., Lupescu, I., Gherghe, M., Becheanu, G. & Croitoru, A. 2020. Somatostatinoma and Neurofibromatosis Type 1-A Case Report and Review of the Literature. *Diagnostics (Basel)*. 2020 Aug 21;10(9):620.

Medscape

<http://emedicine.medscape.com/article/182841-overview#a5>

National Cancer Institute

<http://www.cancer.gov/clinicaltrials/learningabout/what-are-clinical-trials>

Pancreas

<http://medicscientist.com/pancreatitis-inflammatory-disease-pancreas>

Right Diagnosis

<http://www.rightdiagnosis.com/s/somatostatinoma/symptoms.htm>

Stanford School of Medicine

<http://surgpathcriteria.stanford.edu/gitumors/duodenum-somatostatinoma-psammomatous/printable.html>